Xanthoma, xanthelasma, it’s all Greek to me – lipid management in diabetes is more than skin deep…

Guidelines abound setting out specific targets for these lipid sub-fractions, yet clinical trials and real-world data consistently document the failure to achieve these numeric endpoints. Because cardiovascular conditions such as atherosclerotic heart disease and stroke remain the leading cause of death in people with diabetes, reversing this apparent clinical inertia is mandatory. Decades worth of published trials confirm the fundamental place of statins in the treatment paradigm. What then is the role of non-statin treatments?

Join us as together with our expert guest, Prof Dirk Blom, we aim to unpack this aspect of clinical care.